Percutaneous Coronary Intervention 5.1.1. PCI General Considerations: Recommendation Class IIb 1. A strategy of multivessel PCI, in contrast to cul- prit lesion only PCI, may be reasonable in pa- tients undergoing coronary revascularization as part of treatment for NSTE-ACS.330,359 364 (Level of Evidence: B) Approximately half of all PCI procedures are performed in patients with UA or NSTEMI, and approximately 32% to 40% of patients with NSTE-ACS will undergo PCI.365 As discussed previously, in patients with NSTE-ACS, a strategy of early angiography and revascularization (primarily with PCI) results in lower rates of recurrent UA, recurrent reho- spitalization, MI, and death.366,367 Although PCI of a noncul- prit lesion is not advocated in patients with STEMI,26 there is less agreement on whether nonculprit lesions should undergo intervention at the time of culprit-lesion PCI for NSTE-ACS. but not all,330 comparing culprit lesion only PCI with multivessel PCI (eg, PCI of multiple vessels performed at the same time) in patients with NSTE-ACS did not find an increased risk of MACE with multivessel PCI and found a reduction in the need for repeat revascularization. However, the data consist predominantly of post hoc analysis of nonrandomized data with variable duration of follow-up. This question has not been resolved and is an area of current investigation. 5.1.2. PCI Antiplatelet and Anticoagulant Therapy 5.1.2.1. Oral and Intravenous Antiplatelet Agents: Recommendations Class I 1. Patients already taking daily aspirin before PCI should take 81 mg to 325 mg non enteric-coated as- pirin before PCI.26,368 370 (Level of Evidence: B) 2. Patients not on aspirin therapy should be given non enteric- coated aspirin 325 mg as soon as possible be- (Level of Evidence: B) 3. 